To uncover attitudes and the largest challenges going through colorectal most cancers (CRC) consciousness and screening, BGI Genomics launched its State of Colorectal Most cancers Consciousness Report, marking the first-ever international survey report on the world’s third commonest most cancers. This report seeks to encourage motion to deal with the well being challenges of at this time and tomorrow.
This inaugural report seeks to raised perceive the worldwide state of CRC consciousness, in addition to attitudes and actions in direction of CRC screening for common threat teams and CRC screening for hereditary genetic threat teams. 1,817 respondents from six international locations and areas have been surveyed: the U.Ok, Hungary, Saudi Arabia, Thailand, the Chinese language mainland and Hong Kong.
Hungary had the best international incidence charge of colorectal most cancers, with 9,793 circumstances in 2020 primarily based on World Most cancers Analysis Fund . CRC screening participation charge is in Hungary. Worryingly, this report finds Hungary tops the world (52.8%) by way of lack of signs holding them again from screening, far above the worldwide common of 37.0%.
Regardless of 51.5% reporting that there’s inadequate details about CRC and 34.5% citing prices holding them again from CRC screening, the report reveals a number of optimistic findings. For instance, 88.8% are extra prepared to go for screening upon studying in regards to the 5-year survival charge of 90% for early CRC detection.
Picture Credit score: BGI Genomics
Picture Credit score: BGI Genomics
“Early CRC detection affords the most effective consequence for people and healthcare coverage. The remedy price of late-stage CRC is usually greater than ten occasions larger relative to early-stage CRC however with far decrease survival charges,” mentioned Yantao Li, PhD, BGI Genomics Director of Colorectal Most cancers Screening Programme, South-East Asia. “That is why extra international locations or areas are selling early screening applications. For instance, the European Fee is ramping up CRC screening applications.”
Different key takeaways from the report embrace:
Colonoscopy is the best-known screening check, however there’s scope to boost the attention of different exams equivalent to fecal exams. Although colonoscopy (68.2%) is the best-known screening check, it’s dearer and cumbersome relative to fecal testing which is lesser identified at 49.5%. To advertise this extra reasonably priced and versatile choice, fecal testing consciousness must be enhanced.
Medical doctors are the largest issue for respondents to go for screening within the absence of signs. 62.5% will heed their physician’s recommendation to bear CRC screening. Due to this fact, it’s critical that medical doctors are made extra conscious of CRC signs, ask the proper inquiries to determine potential hereditary genetic threat and supply sufferers a variety of screening choices, to suit completely different existence and budgets. In our opinion, the most effective colorectal most cancers screening check is the one a affected person will do.
Respondents are break up when requested about bringing their members of the family for screening. 55.7% are conscious {that a} household historical past of CRC will increase their threat. Based on the Nationwide Complete Most cancers Community (NCCN) pointers, these members of the family ought to begin screening at age 40 or 10 years earlier than the earliest analysis of CRC within the household. The excellent news is that 67.2% who had CRC or a household historical past of CRC have taken their members of the family for screening. Conversely, solely 31.2% of all respondents have taken their members of the family for CRC screening.
To learn and look at nation or region-level comparisons, please see to entry the complete BGI Genomics State of Colorectal Most cancers Consciousness Report 2023.
About BGI Genomics and COLOTECT
, headquartered in Shenzhen China, is the world’s main built-in options supplier of precision medication. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was formally listed on the Shenzhen Inventory Alternate.
Picture Credit score: BGI Genomics
is a non-invasive fecal DNA check developed by BGI Genomics for detecting CRC and precancerous lesions. It makes use of multiplex methylation-specific PCR (MSP) know-how to hint irregular DNA-methylation biomarkers in CRC from stool samples. It has 88% CRC sensitivity, and for early detection, its sensitivity for superior adenoma is 46%, that are each superior to traditional fecal exams.